Aβ1–42 promotes cholinergic sprouting in patients with AD and Lewy body variant of AD
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The neurodegenerative process in Alzheimer's disease (AD) and in the Lewy body variant of AD (LBV) patients is characterized by cholinergic dysfunction and deposition of amyloid beta-peptide (Abeta) 1-40 and 1-42; however, the differential effects of Abeta species on the cholinergic system are not completely clear. OBJECTIVE: To better understand the relationship between levels of Abeta1-40 and 1-42 on cholinergic deficits in AD and LBV patients. METHODS: Levels of choline acetyltransferase (ChAT) activity and ChAT immunoreactivity in the plaques in the frontal cortex of patients with AD and LBV were correlated with Abeta1-42 and 1-40 levels determined by ELISA and with neuropathologic and neurologic markers. RESULTS: Although the overall levels of ChAT activity were reduced in AD and LBV cases, there was a direct correlation with Abeta1-42 levels. Furthermore, patients with high Abeta1-42 levels had more abundant cholinergic dystrophic neurites in the plaques than cases with lower Abeta1-42. CONCLUSION: Abeta1-42 may also trigger cholinergic dysfunction by promoting aberrant neuritic sprouting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856
Self-citationSoluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease
Lue, L.-F., Kuo, Y.-M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., & Rogers, J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65184-x · Cited by 1,530
Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline
Näslund, J. (2000) · JAMA · doi:10.1001/jama.283.12.1571 · Cited by 1,268
DeKosky, S. T., Ikonomovic, M. D., Styren, S. D., Beckett, L., Wisniewski, S., Bennett, D. A., Cochran, E. J., Kordower, J. H., & Mufson, E. J. (2002) · Annals of Neurology · doi:10.1002/ana.10069 · Cited by 686
Wang, J., Dickson, D. W., Trojanowski, J. Q., & Lee, V. M.-Y. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7085 · Cited by 567
Wong, T. P., Debeir, T., Duff, K., & Cuello, A. C. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-07-02706.1999 · Cited by 196
MIRRA, S. S., GEARING, M., MCKEEL, D. W., CRAIN, B. J., HUGHES, J. P., BELLE, G. V., & HEYMAN, A. (1994) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199405000-00012 · Cited by 156
Relationship between plaques, tangles, and loss of cortical cholinergic fibers in alzheimer disease
Geula, C., Mesulam, M. M., Saroff, D. M., & Wu, C.-K. (1998) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199801000-00008 · Cited by 102
Cited by
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
“Moreover, some axonal dystrophic neurites contain either cholinergic, glutamatergic, or gabaergic markers, suggesting a plaqueinduced aberrant sprouting (Benzing et al. 1993; Ferrer et al. 1993; Masliah et al. 2003; Bell et al. 2007).”
Self-citationClassification and basic pathology of Alzheimer disease
Duyckaerts, C., Delatour, B., & Potier, M.-C. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0532-1 · Cited by 1,031
Brain Imaging in Alzheimer Disease
Johnson, K. A., Fox, N. C., Sperling, R. A., & Klunk, W. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006213 · Cited by 875
“2002), aberrant sprouting of cholinergic fibers (Masliah et al. 2003), inefficiency in synaptic transmission (Stern et al.”
BackgroundCelone, K. A., Calhoun, V. D., Dickerson, B. C., Atri, A., Chua, E. F., Miller, S. L., DePeau, K., Rentz, D. M., Selkoe, D. J., Blacker, D., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2250-06.2006 · Cited by 753
Medial temporal lobe function and structure in mild cognitive impairment
Dickerson, B. C., Salat, D. H., Bates, J. F., Atiya, M., Killiany, R. J., Greve, D. N., Dale, A. M., Stern, C. E., Blacker, D., Albert, M. S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20163 · Cited by 566
Metadata
- Authors
- Masliah, E., Alford, M., Adame, A., Rockenstein, E., Galasko, D., Salmon, D., Hansen, L. A., & Thal, L. J.
- Venue
- Neurology
- Published
- 2003-07-22
- Volume
- 61
- Issue
- 2
- Pages
- 206-211
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2125271940
- Cited by
- 53
- References
- 9
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aβ1–42 promotes cholinergic sprouting in patients with AD and Lewy body variant of AD. https://app.cochat.ai/papers/10.1212/01.wnl.0000073987.79060.4b
- The paper
- Masliah, E., Alford, M., Adame, A., Rockenstein, E., Galasko, D., Salmon, D., Hansen, L. A., & Thal, L. J. (2003). Aβ1–42 promotes cholinergic sprouting in patients with AD and Lewy body variant of AD. Neurology. https://doi.org/10.1212/01.wnl.0000073987.79060.4b
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.